From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Tom Winnifrith Bearcast - as Optibiotix shares soar this is why an RNS must be issued

By Tom Winnifrith | Friday 20 December 2019


Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I start where I finished yesterday with Optibiotix (OPTI). Then I look at Bidstack (BIDS), Dev Clever (DEV), Versarien (VRS), Infrastrata (INFA) and NMC Health (NMC)

You must be a paid subscriber to listen to Bearcast
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

TERN

My Tern for a victory lap

Thursday »

HAYD

Haydale – US disaster……Oh Dear!

Wednesday »

Gold

As Gold Battles $3,300, What For The Miners?

 

BOOM

Evil’s Rule: Audioboom

 

URU…Who R U Kidding?

Sunday »

EZJ

BUY Easyjet

Time left: 02:58:33